Orient EuroPharma Co., Ltd.

TPEX:4120 Stock Report

Market Cap: NT$4.2b

Orient EuroPharma Past Earnings Performance

Past criteria checks 1/6

Orient EuroPharma's earnings have been declining at an average annual rate of -53%, while the Pharmaceuticals industry saw earnings growing at 14.7% annually. Revenues have been declining at an average rate of 6.4% per year. Orient EuroPharma's return on equity is 1.5%, and it has net margins of 0.6%.

Key information

-53.0%

Earnings growth rate

-53.0%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate-6.4%
Return on equity1.5%
Net Margin0.6%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Here's Why Orient EuroPharma (GTSM:4120) Has A Meaningful Debt Burden

Apr 04
Here's Why Orient EuroPharma (GTSM:4120) Has A Meaningful Debt Burden

Is Orient EuroPharma Co., Ltd.'s (GTSM:4120) 3.3% Dividend Worth Your Time?

Mar 04
Is Orient EuroPharma Co., Ltd.'s (GTSM:4120) 3.3% Dividend Worth Your Time?

A Look At Orient EuroPharma's (GTSM:4120) Share Price Returns

Feb 10
A Look At Orient EuroPharma's (GTSM:4120) Share Price Returns

Is Orient EuroPharma Co., Ltd.'s (GTSM:4120) Recent Performancer Underpinned By Weak Financials?

Jan 22
Is Orient EuroPharma Co., Ltd.'s (GTSM:4120) Recent Performancer Underpinned By Weak Financials?

We Think Orient EuroPharma (GTSM:4120) Can Stay On Top Of Its Debt

Jan 04
We Think Orient EuroPharma (GTSM:4120) Can Stay On Top Of Its Debt

A Look At The Fair Value Of Orient EuroPharma Co., Ltd. (GTSM:4120)

Dec 17
A Look At The Fair Value Of Orient EuroPharma Co., Ltd. (GTSM:4120)

Are Dividend Investors Getting More Than They Bargained For With Orient EuroPharma Co., Ltd.'s (GTSM:4120) Dividend?

Nov 29
Are Dividend Investors Getting More Than They Bargained For With Orient EuroPharma Co., Ltd.'s (GTSM:4120) Dividend?

Revenue & Expenses Breakdown

How Orient EuroPharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:4120 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 244,545261,843252
31 Dec 234,5921441,870207
30 Sep 234,663-2461,967217
30 Jun 234,668-3982,009214
31 Mar 234,738-3071,995235
31 Dec 224,730-3111,922260
30 Sep 224,727-931,897253
30 Jun 224,767471,854291
31 Mar 224,6961381,869307
31 Dec 214,7671201,915331
30 Sep 214,808-821,921408
30 Jun 214,835-481,959408
31 Mar 215,049871,918371
31 Dec 205,3841991,938367
30 Sep 205,664266656345
30 Jun 205,966311655345
31 Mar 206,141236736373
31 Dec 196,093248747395
30 Sep 195,929233877398
30 Jun 195,832286841407
31 Mar 195,648243748400
31 Dec 185,510247663389
30 Sep 185,3962411,761422
30 Jun 185,3633191,713412
31 Mar 185,2604181,675389
31 Dec 175,2264591,653379
30 Sep 175,2725851,599315
30 Jun 175,2095041,595335
31 Mar 175,2674711,591355
31 Dec 165,2324701,576363
30 Sep 165,0503621,539398
30 Jun 165,0323221,509408
31 Mar 164,8782721,481420
31 Dec 154,9072231,478425
30 Sep 154,9822161,463383
30 Jun 155,0352301,472356
31 Mar 155,1212531,476327
31 Dec 145,0001961,443332
30 Sep 144,8511231,497364
30 Jun 144,6451951,495339
31 Mar 144,6194361,438312
31 Dec 134,6655071,447266
30 Sep 134,6505931,386230

Quality Earnings: 4120 has a large one-off gain of NT$234.7M impacting its last 12 months of financial results to 31st March, 2024.

Growing Profit Margin: 4120 became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4120's earnings have declined by 53% per year over the past 5 years.

Accelerating Growth: 4120 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 4120 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).


Return on Equity

High ROE: 4120's Return on Equity (1.5%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.